Why the study?
Does ridogrel improve coronary patency compared to aspirin as an adjunct to streptokinase in patients with acute myocardial infarction?
Does ridogrel improve coronary patency compared to aspirin as an adjunct to streptokinase in patients with acute myocardial infarction?
Ridogrel is not superior to aspirin for enhancing coronary patency after streptokinase thrombolysis in acute myocardial infarction, but may reduce new ischemic events.
No takes yet. Share an insight, caveat, or question.
Ridogrel is not superior to aspirin for coronary patency after streptokinase; confirms lack of primary benefit and leaves ischemic event reduction open.
A 1994 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: